LDL Particle Distribution and Cardiovascular Risk

Characteristics of LDL Particle Distribution and Clinical Significance

Small, dense LDL particles are more atherogenic than larger LDL particles, and are associated with increased cardiovascular disease risk, according to the American Heart Association 1
Small, dense LDL particles are more susceptible to oxidative modification, making them more atherogenic, as reported by the American College of Cardiology 1

Small, dense LDL particles are often associated with a specific atherogenic phenotype characterized by hypertriglyceridemia, low HDL cholesterol, abdominal obesity, insulin resistance, endothelial dysfunction, and increased thrombosis risk, as described by the American Heart Association 2
This phenotype is generally referred to as "phenotype B" and is characterized by elevated levels of apolipoprotein B (apo B), according to the National Lipid Association 1

In hypertriglyceridemic states, cholesteryl ester transfer protein (CETP) activity leads to triglyceride enrichment of LDL and HDL, resulting in small, dense LDL and HDL particles, as explained by the European Atherosclerosis Society 3, 2

The presence of small, dense LDL particles is associated with increased risk of coronary artery disease (CAD), even when total cholesterol is only slightly elevated, as reported by the American College of Cardiology 1
In patients with type 2 diabetes, small dense LDL particles may be more atherogenic than would be suspected by their concentration alone, as they are more readily oxidized and glycated, according to the American Diabetes Association 4

LDL cholesterol concentration alone may be misleading in patients with small, dense LDL particles, as there will be more LDL particles for any given cholesterol concentration, as noted by the National Lipid Association 4
Non-HDL cholesterol or apolipoprotein B measurements may provide better risk assessment in patients with hypertriglyceridemia, as recommended by the American Heart Association 2

The American Heart Association acknowledges that small, dense LDL particles (phenotype B) are part of an atherogenic phenotype characterized by hypertriglyceridemia, low HDL cholesterol levels, abdominal obesity, and insulin resistance 5, 6
The European Atherosclerosis Society recognizes that the mechanistic link involves cholesteryl ester transfer protein (CETP) activity, which becomes elevated in hypertriglyceridemic states, transferring triglycerides from VLDL into LDL and HDL particles, and subsequent hydrolysis by hepatic triglyceride lipase produces the small, dense LDL phenotype 7

The American Diabetes Association recommends that weight loss and increased physical activity reduce hypertriglyceridemia, which in turn decreases CETP activity and shifts LDL particle distribution toward larger, more buoyant particles 8

The American College of Cardiology notes that LDL particle size is influenced by both dietary and genetic factors and is not necessarily a useful predictor of heart disease risk in isolation, and the ratio of total cholesterol to HDL-C may be a better predictor of coronary artery disease risk than LDL particle size alone 5, 6
The National Lipid Association states that traditional statins effectively lower LDL cholesterol but do not specifically address the small, dense LDL phenotype, and in patients with type 2 diabetes and atherogenic dyslipidemia, statins reduce LDL-C more effectively than fenofibrate, but fenofibrate reduces triglycerides and increases HDL-C to a greater extent 8

Large, buoyant LDL particles have lower density but greater absolute mass because they contain more cholesterol ester per particle 9, 10
Small, dense LDL particles have higher density but carry less cholesterol per particle, making them lighter in absolute terms 10

In hypertriglyceridemic states, cholesteryl ester transfer protein (CETP) activity increases, transferring triglycerides from VLDL into LDL particles, and hepatic triglyceride lipase then hydrolyzes these triglyceride-enriched LDL particles, producing the small, dense phenotype 9

The American Heart Association is not mentioned in the provided citations, however, it is known that measuring LDL particle number can be crucial in certain patient populations, and non-HDL cholesterol or apolipoprotein B measurements provide better cardiovascular risk assessment than LDL-C alone in patients with elevated triglycerides 9, 10
Small, dense LDL particles are more susceptible to oxidation and glycation, particularly in diabetic and insulin-resistant patients 10